1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril

• CAS: 51592-06-4
• Catalog Number: ACM51592064
• Category: Main Products
• Molecular Weight: 432.09
• Molecular Formula: C16H10Cl4N4O2

Case Study

1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril as an Eoxidative Iodination Reagent for Theranostic Nanoplatform

Tao, Yugui, et al. Biomaterials science 9.8 (2021): 2947-2954.

Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenylglycouril) is a mild oxidizing reagent used widely to generate electrophilic iodine species for direct electrophilic radioiodination of aromatic rings and other activated positions on biomolecules and nanomaterials. This work reported the use of iodogen to install radioactive iodine (¹²⁵I) onto PEG-modified zirconium-based nMOF particles (PCN-PEG) intended for tumor imaging and radioisotope therapy.
¹²⁵I Radiolabeling Procedure: Iodogen was first dissolved in chloroform (5 mg/mL), applied to the inner wall of a centrifuge tube, and evaporated under nitrogen to create a fixed oxidative coating. A PBS suspension of PCN-PEG nanoparticles (TCPP concentration 0.233 mg/mL) was then added directly to the Iodogen-coated tube along with the radioiodine source, followed by incubation at 37 °C for 60 minutes with continuous shaking. After the reaction, the ¹²⁵I-labeled PCN-PEG product was purified using a 10 kDa ultrafiltration membrane, allowing unbound iodine to be removed. The procedure achieved a 51% radiolabeling yield for attaching ¹²⁵I to the PCN-PEG nMOF.

1,3,4,6-Tetrachloro-3α,6α-diphenylglycouril for Oxidative Radioiodination of Phenytoin to Produce ¹³¹I-PHT for in-vitro Tumor Cell

Uzaras, Cansu, et al. Journal of Radioanalytical and Nuclear Chemistry 307.1 (2016): 131-140.

The development of targeted radionuclide therapy represents a promising strategy for treating cancers, including challenging central nervous system (CNS) tumors. A critical step in this process is the stable and efficient conjugation of a therapeutic radioisotope, such as Iodine-131 (¹³¹I), to a biologically active targeting molecule. This study reported the application of 1,3,4,6-tetrachloro-3α,6α-diphenylglycouril, commercially known as Iodogen, for the radiolabeling of the anti-epileptic drug Phenytoin (PHT). Cell culture uptake studies using U-87 MG, Daoy and A549 cell lines demonstrated a decrease in the rate of incorporation of ¹³¹I-PHT with increasing radioactivity intensity in all three cell lines. It is concluded that ¹³¹I-PHT may be a promising radiopharmaceutical for the targeted therapy of CNS tumors.
Iodogen protocol & radiolabeling: Dissolve 1 mg Iodogen in 1 mL dichloromethane, add to glass tube and evaporate solvent to leave a thin film of Iodogen on the tube wall. Store coated tubes at +4 °C until use. Add 1 mg PHT and 1 mCi (37 MBq) ¹³¹I separately into an Iodogen-coated tube and incubate for 30 min at room temperature with gentle mixing. Remove unbound radioiodide and assess products. Perform parallel iodination using stoichiometric K¹²⁷I and Iodogen; analyze the cold product by HPLC to verify identity. The radiochemical yield of ¹³¹I-PHT was 96 ± 0.8%.